Corbus Pharmaceuticals Holdings (CRBP) Non Operating Investment Income (2022 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly Non Operating Investment Income of -$58000.0 in Q1 2025, up 82.26% quarter-over-quarter from -$326949.0 in Q1 2024, and up 82.26% on a YoY basis from -$31822.6 in Q1 2024.
Corbus Pharmaceuticals Holdings (CRBP) Non Operating Investment Income (2022 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$58000.0 for Q1 2025.
- In Q1 2025, Non Operating Investment Income rose 82.26% year-over-year to -$58000.0; the TTM figure through Mar 2025 stood at -$362717.0 (down 39.49% YoY), while the FY2023 annual figure was $124536.0, up 295.67% from the prior year.
- Non Operating Investment Income was -$58000.0 for Q1 2025 at Corbus Pharmaceuticals Holdings, up from -$326949.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $80782.0 in Q4 2022 to a low of -$326949.0 in Q1 2024.
- Historically, Non Operating Investment Income has averaged -$32406.0 across 4 years, with a median of $11116.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Non Operating Investment Income surged 153.73% in 2023, then tumbled 667.39% in 2024.
- A 4-year view of Non Operating Investment Income shows it stood at $80782.0 in 2022, then sank by 91.98% to $6479.0 in 2023, then slumped by 5146.29% to -$326949.0 in 2024, then jumped by 82.26% to -$58000.0 in 2025.
- The last three Non Operating Investment Income figures came in at -$58000.0 (Q1 2025), -$326949.0 (Q1 2024), and $6479.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 230,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 135.08 Mn | 107.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -58,000.00 |
| Mar 31, 2025 | -58,000.00 |
| Mar 31, 2024 | -326,949.00 |
| Mar 31, 2024 | -326,949.00 |
| Dec 31, 2023 | 6,479.00 |
| Dec 31, 2023 | 6,479.00 |
| Sep 30, 2023 | 15,753.00 |
| Sep 30, 2023 | 15,753.00 |
| Jun 30, 2023 | 44,681.00 |
| Jun 30, 2023 | 44,681.00 |
| Mar 31, 2023 | 57,623.00 |
| Mar 31, 2023 | 57,623.00 |
| Dec 31, 2022 | 80,782.00 |
| Dec 31, 2022 | 80,782.00 |
| Sep 30, 2022 | -87,554.00 |
| Sep 30, 2022 | -87,554.00 |
| Jun 30, 2022 | 50,373.00 |
| Jun 30, 2022 | 50,373.00 |
| Mar 31, 2022 | -107,248.00 |
| Mar 31, 2022 | -107,248.00 |